- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst | 175 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - September 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial... ► Artikel lesen | |
| 19.08. | Karolinska Development AB (publ): Interim Report - January-June 2021 | 4 | GlobeNewswire (USA) | ||
| KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln | |||||
| 16.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market | 278 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - August 16, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has launched OssDsign Catalyst in the U.S. The product... ► Artikel lesen | |
| 12.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program | 292 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics... ► Artikel lesen | |
| 22.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt | 269 | GlobeNewswire (Europe) | STOCKHOLM SWEDEN - July 22, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Aprea Therapeutics has reported positive results from a Phase 2 trial... ► Artikel lesen | |
| 15.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing | 259 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - July 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Modus Therapeutics has completed an oversubscribed issue of units (113%... ► Artikel lesen | |
| 14.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue | 255 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - July 14, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition has carried out a directed new share issue of SEK... ► Artikel lesen | |
| 07.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical | 205 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - July 7, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Promimic has received a shared 501(k) clearance from the U.S. Food and... ► Artikel lesen | |
| 07.07. | Karolinska Development AB (publ): Karolinska Development sells its holding in Lipidor AB and receives a net of SEK 4 million | 276 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - July 7, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has sold its entire holding in the listed portfolio company Lipidor AB. In total... ► Artikel lesen | |
| 17.06. | Karolinska Development AB (publ): Karolinska Development expands its portfolio through new investment in AnaCardio | 1 | GlobeNewswire (USA) | ||
| 17.06. | Karolinska Development AB (publ): Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million | 1 | GlobeNewswire (USA) | ||
| 17.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia | 368 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase... ► Artikel lesen | |
| 15.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria | 228 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - June 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has entered into a collaboration agreement with Imperial... ► Artikel lesen | |
| 11.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth ... | - | GlobeNewswire (USA) | ||
| 10.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen raises SEK 50 million through a successful unit offering and prepares for IPO | 397 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - June 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering... ► Artikel lesen | |
| 01.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparin | 1 | GlobeNewswire (USA) | ||
| 21.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market | 243 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN 21 May 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Umecrine Cognition is preparing a listing on Nasdaq First North Growth Market... ► Artikel lesen | |
| 12.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue | 318 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential... ► Artikel lesen | |
| 05.05. | Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 2021 | 2 | GlobeNewswire (USA) | ||
| 29.04. | Karolinska Development AB (publ): Interim Report - January-March 2021 | - | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GLAXOSMITHKLINE | 16,400 | -1,20 % | Schottischer Pharmastandort Montrose: Bilfinger erhält Instandhaltungs-Auftrag von GSK | Der Industriedienstleister Bilfinger hat vom Pharmakonzern Glaxosmithkline (GSK) einen Projekt- und Instandhaltungsvertrag für die Produktionsanlagen in Montrose, Schottland erhalten. Der Dreijahresvertrag... ► Artikel lesen | |
| BAYER | 45,210 | -0,94 % | BASF - Das darf jetzt nicht passieren. Bayer - Aktie in prekärer Lage. | Für unsere beiden heutigen Protagonisten BASF und Bayer brechen wichtige womöglich auch richtungsweisende Handelstage an. Während Bayer bereits zuletzt einen herben charttechnischen Rückschlag hinnehmen... ► Artikel lesen | |
| MERCK KGAA | 196,50 | +0,08 % | Merck-Chefin Belen Garijo baut auf Pharmageschäft | Die Corona-Pandemie hat Merck-Chefin Belen Garijo einen glänzenden Amtsantritt beschert. Zweimal schon konnte der Dax-Konzern in diesem Jahr seine Ziele anheben, denn die weltweite Forschung nach Covid-19-Impfstoffen... ► Artikel lesen | |
| POINT BIOPHARMA GLOBAL | 10,070 | +5,56 % | POINT Biopharma partners with Convergent Therapeutics in prostate cancer study | ||
| ROCKET LAB USA | 15,410 | -3,02 % | Rocket Lab swaps top industrial gainer tag for loser while Lion Electric drives to #1 spot | ||
| DERMAPHARM | 84,75 | 0,00 % | Dermapharm Holding: Super-Treffer mit + 140%! Kommt wieder ein neues Allzeithoch? | Am 03. August hatten wir im Express-Service auf eine gute Trading-Chance bei Dermapharm Holding ISIN: DE000A2GS5D8 hingewiesen. Der Beitrag hatte folgenden Titel: "Dermapharm Holding: Der Anstieg zum... ► Artikel lesen | |
| INNOCAN PHARMA | 0,855 | -17,79 % | Unfassbare Rallye - 100% Strong Buy! Zwei Asse in der Hand?! | ||
| CLARUS THERAPEUTICS | 8,810 | +12,52 % | Clarus Therapeutics, McGill University Ink Licensing Pact For Rare CoQ10-Associated Conditions | ||
| PFIZER | 37,450 | -0,93 % | Aktien: CureVac verliert die Hoffnung - Aktie stürzt ab | ||
| HARROW HEALTH | 9,490 | +3,26 % | Harrow Health: Garantierte 7,2% Rendite p.a. bis 2026 - so geht's! | Einkommensinvestoren haben einen zunehmend schwereren Stand: Die Renditen für REITs, Dividenden-Aktien, US-Vorzugsaktien und Anleihen sinken erbarmungslos. Wer sein Rendite-Niveau erhalten möchte, muss... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,170 | +0,48 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| NOVO NORDISK | 86,52 | -0,75 % | JEFFERIES stuft NOVO NORDISK auf 'Underperform' | NEW YORK (dpa-AFX Analyser) - Die Investmentbank Jefferies hat das Kursziel für Novo Nordisk von 415 auf 465 dänische Kronen angehoben, die Einstufung aber auf "Underperform" belassen. Der Analyst Peter... ► Artikel lesen | |
| ESSA PHARMA | 8,850 | +3,03 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 18.08.2021 | The following instruments on XETRA do have their last trading day on 18.08.2021Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 18.08.2021ISIN Name
US68243Q1067 1-800-FLOWERS.COM... ► Artikel lesen | |
| ABBVIE | 92,13 | +0,30 % | AbbVie kündigt konstante Dividende an | Der amerikanische Pharmakonzern AbbVie Inc. (ISIN: US00287Y1091, NYSE: ABBV) zahlt eine Quartalsdividende von 1,30 US-Dollar je Aktie an seine Investoren, wie am Freitag berichtet wurde. Die Zahlung... ► Artikel lesen | |
| TILRAY | 10,350 | +1,42 % | Tilray Inc.: Das ist gar nicht gut | Innerhalb eines schwächelnden Cannabis-Sektors gelingt es auch der Tilray-Aktie derzeit nicht, Aufwärtsmomentum zu kreieren. Innerhalb eines schwächelnden Cannabis-Sektors gelingt es auch der Tilray-Aktie... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
